Yorktown Management & Research Company’s Ionis Pharmaceuticals IONS Stock Holding History

Yorktown Management & Research Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Buy	+4,400	New	+$331K	0.21%	184

Other funds holding IONS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Yorktown Management & Research Company's IONS Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 4,400 shares worth $349K. The stake represents 0.21% of the portfolio and ranks #184 among its holdings.

240 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Yorktown Management & Research Company held 4,400 shares of Ionis Pharmaceuticals worth $349K as of Q2 2026.
Ionis Pharmaceuticals was a new Yorktown Management & Research Company position in Q2 2026.
Ionis Pharmaceuticals made up 0.21% of Yorktown Management & Research Company's portfolio in Q2 2026, its #184 holding.
240 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.